TY - JOUR. T1 - Decreased homing of retrovirally transduced human bone marrow CD34 + cells in the NOD/SCID mouse model. AU - Hall, Kristin M.. AU - Horvath, Tamara L.. AU - Abonour, Rafat. AU - Cornetta, Kenneth. AU - Srour, Edward F.. PY - 2006/4/1. Y1 - 2006/4/1. N2 - Objective. Many clinical gene therapy trials have described poor engraftment of retrovirally transduced CD34+ cells. Because engraftment is dependent upon successful homing of graft cells to the bone marrow (BM), we examined whether retroviral-mediated gene transfer (RMGT) induces a homing defect in CD34+ cells. Methods. Homing of fluorescently labeled human BM CD34+ cells transduced with three separate retroviral vectors (MFG-eGFP, LNC-eGFP, and LXSN) was assessed in nonobese diabetic/severe combined immunodeficient mice. Results. Homing of transduced CD34+ cells was significantly decreased 20 hours after transplantation compared with freshly isolated control and cultured untransduced control cells. Specifically, homing of GFP+ ...

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience ...

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon. ...

Background: CD31, PECAM-1 has been used as a marker for endothelial cells. However, recent data have indicated that CD31 is also expressed at an early developmental stage. We hypothesized that CD31 could serve as a comprehensive epitope to encircle various subsets of hemangioblastic cells in adult bone marrow (BM).. Methods and Results: A fraction of CD31+ cells of BM mononuclear cells in C57BL/6 mice co-expressed well known stem cell markers including c-kit, Sca-1, and flk-1. The expression levels of these markers were distinct when hematopoietic lineage positive cells were depleted (Lin−) from CD31+ cells. Moreover, Lin−CD31+ cells exclusively expressed genes characterizing pluripotency such as Oct4, Rex4, Nanog, and SSEA-1.A microarray revealed that CD31+ cells expressed multiple angiogenic genes compared to CD31− cells. In particular, only a CD31+ but not CD31− fraction gave rise to endothelial progenitor cells (EPCs) in a culture assay. To determine in vivo activity, we performed BM ...

Top 10 tissues for NP_776216 (Homo sapiens, RefSeq): peripheral blood anergic B-cell, peripheral blood CD4 resting T-cell (unspecified), peripheral blood CD4 memory regulatory T-cell, peripheral blood CD4 naive regulatory T-cell, tumor derived CD4 T-cell (unspecified), peripheral blood CD4 memory T-cell (unspecified), peripheral blood CD8 activated T-cell (unspecified), tonsillar activated T-cell (unspecified), bone marrow CD4 T-cell (unspecified), gingival epithelium organotypic model

title: Impaired function and epigenetic changes of human cord blood-derived CD133+/C-kit+Lin- endothelial progenitor cells in preeclampsia, doi: none, category: Thesis

TY - JOUR. T1 - Drosophila forkhead homologues are expressed in CD34+HLA-DR- primitive human hematopoietic progenitors. AU - Hromas, Robert. AU - Klemsz, Michael. AU - Amaravadi, Lakshmi. AU - Hufford, Tricia. AU - Huang, Irene. AU - Desai, Alpana. AU - Srour, Edward. AU - Bruno, Edward. AU - Hoffman, Ronald. PY - 1994. Y1 - 1994. N2 - The Forkhead gene (FKH) regulates morphogenesis in Drosophila. It is the prototype of a new family of transcriptional activators. We used the polymerase chain reaction (PCR) to analyze the expression pattern of this new transcriptional regulatory gene family in primitive hematopoeitic progenitors. Partially degenerate oligonucleotides to two conserved amino acid sequences of this family were used to prime a PCR amplification of cDNA synthesized from CD34+HLA-DR- hematopoietic cells. Known and novel FKH genes were found to be expressed in these cells.. AB - The Forkhead gene (FKH) regulates morphogenesis in Drosophila. It is the prototype of a new family of ...

TY - JOUR. T1 - Upregulation of IL-5 receptor expression on bone marrow-derived CD34+ cells from patients with asthma.. AU - Chou, C. L.. AU - Wang, C. H.. AU - Kuo, H. P.. PY - 1999/1/1. Y1 - 1999/1/1. N2 - BACKGROUND: Interleukin-5 (IL-5) is a potent eosinophilopoietic factor implicated in the chronic inflammatory cell accumulation accompanying bronchial asthma. We studied the expression of the IL-5 receptor alpha-subunit (IL-5R alpha) on bone marrow-derived cluster of differentiation molecule 34 positive (CD34+) progenitor cells in asthmatics to prove the ability of progenitor cells to respond to IL-5 more readily. METHODS: Non-adherent non-T cells (NANT) were separated from heparinized bone marrow blood from 6 asthmatics and 3 normal subjects, loaded with CD34+ and IL-5R alpha monoclonal antibodies conjugated with immunofluorescence and then analyzed by flow cytometry. Colonies grown from progenitor cells cultured in methylcellulose were determined for 14 days in the presence or absence of ...

Hematopoiesis depends on the association of hematopoietic stem cells with stromal cells that constitute the hematopoietic microenvironment. The in vitro development of the endothelial cell from umbilical cord blood (UCB) is not well established and has met very limited success. In this study, UCB CD34(+) cells were cultured for 5 weeks in a stroma-free liquid culture system using thrombopoietin, flt3 ligand, and granulocyte-colony stimulating factor. By week 4-5, we found that firmly adherent fibroblast-like cells were established. These cells showed characteristics of endothelial cells expressing von Willebrand factor, human vascular cell adhesion molecule-1, human intracellular adhesion molecule-1, human CD31, E-selectin, and human macrophage. Furthermore, when comparing an ex vivo system without an established endothelial monolayer to an ex vivo system with an established endothelial monolayer, better expansion of total nucleated cells, CD34(+) cells, and colony-forming units ...

TY - JOUR. T1 - Generation and function of progenitor t cells from stemregenin-1-expanded CD34+ human hematopoietic progenitor cells. AU - Singh, Jastaranpreet. AU - Chen, Edward L.Y.. AU - Xing, Yan. AU - Stefanski, Heather E.. AU - Blazar, Bruce R.. AU - Zúñiga-Pflücker, Juan Carlos. PY - 2019. Y1 - 2019. N2 - Broader clinical application of umbilical cord blood (UCB), as a source of hematopoietic stem/progenitor cells (HSPCs), is limited by low CD34+ and T-cell numbers, contributing to slow lymphohematopoietic recovery, infection, and relapse. Studies have evaluated the safety, feasibility, and expedited neutrophil recovery associated with the transplantation of CD34+ HSPCs from ex vivo expansion cultures using the aryl hydrocarbon receptor antagonist StemRegenin-1 (SR1). In a phase 1/2 study of 17 patients who received combined SR1-expanded and unexpanded UCB units, a considerable advantage for enhancing T-cell chimerism was not observed. We previously showed that progenitor T (proT) ...

Several studies have previously demonstrated enrichment in primitive progenitor cells in subfractions of CD34+bone marrow (BM) cells not expressing CD38 or HLA-DR (DR) antigens. However, no studies have directly compared these two cell populations with regard to their content of primitive and more committed progenitor cells. Flow cytometric analysis of immunomagnetic isolated CD34+cells demonstrated little overlap between CD34+CD38-and CD34+DR-progenitor subpopulations in that only 12% to 14% of total CD34+DR-and CD34+CD38-cells were double negative (CD34+CD38-DR-). Although the number of committed myeloid progenitor cells (colony- forming units granulocyte-macrophage) was reduced in both subpopulations, only CD34+CD38-cells were significantly depleted in committed erythroid progenitor cells (burst-forming units-erythroid). In single-cell assay, CD34+CD38-cells showed consistently poorer response to single as opposed to multiple hematopoietic growth factors as compared with unfractionated CD34+cells,

AllCells offers a wide selection of human primary cells and related products including Bone Marrow CD34+ Stem/Progenitor Cells from our AllCells.com store.

The present invention relates to an antibody composition which contains antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, and optionally CD45RA, CD38, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and/or antibodies specific for antigens expressed on non-hematopoietic tumor cells. A process is also provided for enriching and recovering human hematopoietic progenitor cells and stem cells in a sample containing human hematopoietic differentiated, progenitor, and stem cells, and optionally tumor cells. The process involves reacting the sample with an antibody composition containing antibodies capable of binding to the antigens glycophorin A, CD3 CD24, CD16, and CD14, and optionally CD45RA, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and/or antibodies specific for antigen expressed on non-hematopoietic tumor cells under conditions so that cell conjugates are formed between the antibodies and differentiated cells having the antigens glycophorin A, CD3 CD24, CD16, and CD14, and optionally CD45RA, CD38,

AllCells offers a wide selection of human primary cells and related products including Bone Marrow CD105+ Endothelial Cells from our AllCells.com store.

CD133 is a novel 5-transmembrane cell surface antigen with a molecular weight of 117 kDa. CD133/2 (AC141) antibodies recognize epitope 2 of the human CD133 antigen (CD133/2). In the hematopoietic system, CD133 expression is restricted to a subset of CD34bright stem and progenitor cells in human fetal liver, bone marrow, cord blood and peripheral blood. Additionally, CD133 is expressed by a small portion of CD34- cells in these tissues. The CD34+ CD133+ cell population, which includes CD34+ CD38- cells, was shown to be capable of repopulating NOD/SCID mice. Recently, CD133 has also been found to be expressed on endothelial precursor cells and fetal neural stem cells as well as on developing epithelium. The putative murine homologue, prominin, which is expressed on neuroepithelial and epithelial mouse cells, was identified. In contrast to the other CD133 clones, the clone AC141 shows cross-reactivity with the intracellular protein cytokeratin 18. - USA

CD133 is a novel 5-transmembrane cell surface antigen with a molecular weight of 117 kDa. CD133/2 (AC141) antibodies recognize epitope 2 of the human CD133 antigen (CD133/2). In the hematopoietic system, CD133 expression is restricted to a subset of CD34bright stem and progenitor cells in human fetal liver, bone marrow, cord blood and peripheral blood. Additionally, CD133 is expressed by a small portion of CD34- cells in these tissues. The CD34+ CD133+ cell population, which includes CD34+ CD38- cells, was shown to be capable of repopulating NOD/SCID mice. Recently, CD133 has also been found to be expressed on endothelial precursor cells and fetal neural stem cells as well as on developing epithelium. The putative murine homologue, prominin, which is expressed on neuroepithelial and epithelial mouse cells, was identified. In contrast to the other CD133 clones, the clone AC141 shows cross-reactivity with the intracellular protein cytokeratin 18. - USA

Our leukapheresis products are typically sourced from healthy donors and contain 5-20 billion white blood cells, plasma, platelets & few red blood cells.

Giannoni, Francesca and Hardee, Cinnamon L. and Wherley, Jennifer et al. (2013) Allelic Exclusion and Peripheral Reconstitution by TCR Transgenic T Cells Arising From Transduced Human Hematopoietic Stem/Progenitor Cells. Molecular Therapy, 21 (5). pp. 1044-1054. ISSN 1525-0016. PMCID PMC3666644. https://resolver.caltech.edu/CaltechAUTHORS:20130702-113609364 ...

ABCell-Bio offers its CD133+ hematopoietic progenitors carefully isolated from umbilical cord blood, an excellent alternative source of Hematopoietic Stem Cells. Our CD133+ hematopoietic progenitors are subject to many quality controls, certifying their virologic compliance, performance, purity and viability. We can supply CD133 + cells with a purity above 95%.

in Transfusion (1998), 38(2), 199-208. BACKGROUND: A study of CD34+ cell selection and transplantation was carried out with particular emphasis on characteristics of short- and long-term hematopoietic recovery. STUDY DESIGN AND METHODS ... [more ▼]. BACKGROUND: A study of CD34+ cell selection and transplantation was carried out with particular emphasis on characteristics of short- and long-term hematopoietic recovery. STUDY DESIGN AND METHODS: Peripheral blood stem and progenitor cells (PBPCs) were collected from 32 patients, and 17 CD34+ cell-selection procedures were carried out in 15 of the 32. One patient in whom two procedures failed to provide 1 x 10(6) CD34+ cells per kg was excluded from further analysis. After conditioning, patients received CD34+ cells (n = 10, CD34 group) or unmanipulated (n = 17, PBPC group) PBPCs containing equivalent amounts of CD34+ cells or progenitors. RESULTS: The yield of CD34+ cells was 53 percent (18-100) with a purity of 63 percent (49-82). The CD34+ ...

TY - JOUR. T1 - Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning. T2 - The effect of postgrafting mycophenolate mofetil dosing. AU - Maris, Michael B.. AU - Sandmaier, Brenda M.. AU - Storer, Barry E.. AU - Maloney, David G.. AU - Shizuru, Judith A.. AU - Agura, Edward. AU - Kliem, Constanze. AU - Pulsipher, Michael. AU - Maziarz, Richard T.. AU - McSweeney, Peter A.. AU - Wade, James. AU - Langston, Amelia A.. AU - Chauncey, Thomas R.. AU - Bruno, Benedetto. AU - Blume, Karl G.. AU - Storb, Rainer. PY - 2006/4/1. Y1 - 2006/4/1. N2 - We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m2, 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg ...

CFU-GM - Colony-Forming Unit-Granulocyte and Monocyte. Looking for abbreviations of CFU-GM? It is Colony-Forming Unit-Granulocyte and Monocyte. Colony-Forming Unit-Granulocyte and Monocyte listed as CFU-GM

Hematopoietic stem/progenitor cells (HSPCs) maintain the hematopoietic system by balancing their self-renewal and differentiation events. Hematopoietic stem cells also migrate to various sites and interact with their specific microenvironment to maintain the integrity of the system. Rho GTPases have been found to control the migration of hematopoietic cells and other cell types. Although the role of RAC1, RAC2 and CDC42 has been studied, the role of RHOA in human hematopoietic stem cells is unclear. By utilizing constitutively active and dominant negative RHOA, we show that RHOA negatively regulates both in vitro and in vivo migration and dominant negative RHOA significantly increased the migration potential of human HSC/HPCs. Active RHOA expression favors the retention of hematopoietic stem/progenitor cells in the niche rather than migration and was found to lock the cells in the G0 cell cycle phase thereby affecting their long-term self-renewal potential. The current study demonstrates that down

Recent developments of surrogate assays for human hematopoietic stem cells (HSC) have facilitated efforts at improving HSC gene transfer efficiency. Through the use of xenograft transplantation models, such as nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice, successful oncoretroviral gene transfer to transplantable hematopoietic cells has been achieved. However, because of the low frequency and/or homing efficiency of SCID repopulating cells (SRC) in bone marrow (BM), studies have primarily focused on cord blood (CB). The recently developed extended (| 60 days) long-term culture-initiating cell (ELTC-IC) assay detects an infrequent and highly quiescent candidate stem cell population in BM as well as CB of the CD34(+)CD38(-) phenotype. Although these characteristics suggest that ELTC-IC and SRC might be closely related, attempts to oncoretrovirally transduce ELTC-IC have been unsuccessful. Here, recently developed conditions (high concentrations of SCF + FL + Tpo in serum-free medium)

The only curative therapy for sickle cell disease (SCD) is allogeneic hematopoietic stem cell (HSC) transplantation. Gene therapy approaches for autologous HSC transplantation are being developed. Although earlier engraftment is seen when cells from GCSF-mobilized blood are transplanted than when bone marrow is transplanted, administration of GCSF to patients with SCD can cause significant morbidity. We tested whether primitive hematopoietic progenitors are spontaneously mobilized in the blood of patients with SCD during acute crisis (AC-SCD patients). The frequency of myeloid-lymphoid-initiating cells (ML-ICs) and SCID-repopulating cells (SRCs) was significantly higher in blood from AC-SCD patients than in blood from patients with steady-state SCD or from normal donors. The presence of SRCs in peripheral blood was not associated with detection of long-term culture-initiating cells, consistent with the notion that SRCs are more primitive than long-term culture-initiating cells. As ML-ICs and ...

Human umbilical cord blood derived CD34+ stem cells are reported to mediate therapeutic effects in stroke animal models. Estrogen was known to protect against ischemic injury. The present study wished to investigate whether the protective effect of CD34+ cells against ischemic injury can be reinforced with complemental estradiol treatment in female ovariectomized rat and its possible mechanism. Experiment 1 was to determine the best optimal timing of CD34+ cell treatment for the neuroprotective effect after 60-min middle cerebral artery occlusion (MCAO). Experiment 2 was to evaluate the adjuvant effect of 17β-estradiol on CD34+ cell neuroprotection after MCAO. Experiment 1 showed intravenous infusion with CD34+ cells before MCAO (pre-treatment) caused less infarction size than those infused after MCAO (post-treatment) on 7T magnetic resonance T2-weighted images. Experiment 2 revealed infarction size was most significantly reduced after CD34+ + estradiol pre-treatment. When compared with no treatment

Since tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and transforming growth factor (TGF)-beta have all been shown to be specific inhibitors of early human hematopoiesis, we wanted to investigate the interactions of these three cytokines on very primitive human adult bone marrow CD34++CD38- hematopoietic progenitor cells, using a pre-colony-forming cell (pre-CFC) assay, which detects the effects of these cytokines on the initial phases of the differentiation of these primitive progenitors, which are unresponsive to interleukin (IL) 3 alone. Surprisingly, TNF-alpha was a very potent stimulator of the proliferation of CD34++CD38- cells and was the most potent synergistic factor for the IL-3-induced proliferation of these cells of all cytokines tested (IL-1, IL-6, granulocyte colony-stimulating factor, kit ligand). TNF-alpha was the only cytokine that, as a single added factor, induced substantial proliferation in CD34++CD38- cells in the presence of IL-3, except for kit ligand, which ...

This study enumerated CD45hi/CD34+ and CD45hi/CD133+ human hematopoietic stem cells (HSC) and granulocyte-monocyte colony forming (GM-CFC) progenitor cells in blood and trochanteric and femoral bone marrow in 233 individuals. (SP) multipotential HSC, that are the precursors of CD45hi/CD133+ and CD45hi/CD34+, decline with age. Potentially the increases in stem cell frequencies in the intermediate compartment between SP and GM progenitor cells observed in this study represent a compensatory increase for the loss of more potent members of the HSC hierarchy. testis cause a decline in germ cell self-renewal 40. To test the hypothesis, 233 human subjects, of ages between 21 and 88 years, undergoing hip replacement surgery were enrolled in an IRB approved research which enumerated the SP HSC, Compact disc34+ and Compact disc133+ HSC by movement cytometry and myeloid colony developing cells (GM-CFC) in tradition through the bone marrow from the trochanteric area from the femoral diaphysis and femoral ...

Megan D. Hoban, Gregory J. Cost, Matthew C. Mendel, Zulema Romero, Michael L. Kaufman, Alok V. Joglekar, Michelle Ho, Dianne Lumaquin, David Gray, Georgia R. Lill, Aaron R. Cooper, Fabrizia Urbinati, Shantha Senadheera, Allen Zhu, Pei-Qi Liu, David E. Paschon, Lei Zhang, Edward J. Rebar, Andrew Wilber, Xiaoyan Wang, Philip D. Gregory, Michael C. Holmes, Andreas Reik, Roger P. Hollis, Donald B. Kohn. ...

Holmes, T., Yan, F., Ko, K.-H., Nordon, R., Song, E., OBrien, T. A. and Dolnikov, A. (2012), Ex vivo expansion of cord blood progenitors impairs their short-term and long-term repopulating activity associated with transcriptional dysregulation of signalling networks. Cell Proliferation, 45: 266-278. doi: 10.1111/j.1365-2184.2012.00813.x ...

Expression of Thy-1 on hematopoietic cells from human fetal liver (FL), cord blood (CB), and bone marrow (BM) was studied with a novel anti-Thy-1 antibody, 5E10. Specificity of 5E10 for human Thy-1 was demonstrated by immunoprecipitation of a 25-35-kD molecule, and the sequence of a cDNA that was cloned by immunoselection of COS cells transfected with a cDNA library derived from a 5E10+ cell line. Two- and three-color immunofluorescence staining experiments revealed that the Thy-1 expression is restricted to, an average, 1-4% of FL, CB, and BM cells, and binding to these cell types is essentially restricted to a very small subset of lymphoid cells and approximately 25% of CD34+ cells. Thy-1+ CD34+ cells were further characterized as CD38lo/CD45RO+/CD45RA-/CD71lo/c-kit(lo) and rhodamine 123dull. When CD34+ cells were sorted on the basis of Thy-1 expression, the majority of clonogenic cells were recovered in the CD34+Thy-1- fraction, whereas the majority of cells capable of producing myeloid ...

Oxidative metabolism and redox signaling prove to play a decisional role in controlling adult hematopoietic stem/progenitor cells (HSPCs) biology. However, HSPCs reside in a hypoxic bone marrow microenvironment raising the question of how oxygen metabolism might be ensued. In this study, we provide for the first time novel functional and molecular evidences that human HSPCs express myoglobin (Mb) at level comparable with that of a muscle-derived cell line. Optical spectroscopy and oxymetry enabled to estimate an O-2-sensitive heme-containing protein content of approximately 180 ng globin per 10(6) HSPC and a P-50 of approximately 3 mu M O-2. Noticeably, expression of Mb mainly occurs through a HIF-1-induced alternative transcript (Mb-V/Mb-N = 35 +/- 15, p , .01). A search for other Mb-related globins unveiled significant expression of neuroglobin (Ngb) but not of cytoglobin. Confocal microscopy immune detection of Mb in HSPCs strikingly revealed nuclear localization in cell subsets expressing ...

PURPOSE: To support multicyclic, dose-intensive chemotherapy, we assessed the effects of reinfusing hematopoietic progenitors collected at each cycle in leukapheresis product or whole blood. PATIENTS AND METHODS: Twenty-five patients with small-cell lung cancer (SCLC) were treated with six cycles of ifosfamide, carboplatin, and etoposide (ICE) with granulocyte colony-stimulating factor (G-CSF) 300 micrograms/d subcutaneously (SC) on days 4 to 15. Hematopoietic progenitors collected during each cycle were reinfused on day 3 of the next cycle. Cohort 1 (n = 6) was treated every 3 weeks, with leukapheresis after 2 weeks and cryopreservation of the leukapheresis product. Chemotherapy was given if the WBC count was , or = 3 x 10(9)/L and platelet count , or = 100 x 10(9)/L. Cohort 2 (n = 7) was treated every 2 weeks, with leukapheresis on day 1 of the next cycle and storage of the leukapheresis product at 4 degrees C. Cohort 3 (n = 12) was treated every 2 weeks, with 500 to 750 mL of blood drawn by ...

Hematopoietic progenitor cells, cord blood is used for blood cell transplantation procedures in patients with disorders that affect blood production. This medicine is derived from human blood that is collected from the umbilical cord and placenta. The hematopoietic progenitor cells go to the bone marrow where they become red blood cells, white blood cells, or platelets. These cells enter the blood stream and help restore low blood counts in patients with blood disorders. ...

Abstract. Evidence has been provided recently that shows that high concentrations of cytokines can fulfill functions previously attributed to stromal cells, su

AABB Hematopoietic Progenitor Cell (HPC) activities include educational programs, publications and accreditation for HPC programs.. The list of AABB Accredited HPC Facilities specifies those HPC facilities, in the US and throughout the world, which have attained AABB accreditation. These facilities are responsible for procuring, processing and storing hematopoietic progenitor cells that can be used for transplantation.. ...

The CD109 antigen is a monomeric glycosyl phosphatidylinositol (GPI)-linked glycoprotein of 170 kDa that contains several N-linked endoglycosidase H-sensitive hybrid-type glycans but no O-linked glycan. It has been reported as a novel member of the α2 macroglobulin (α2M) / C3, C4, C5 family of thioester-containing proteins. The CD109 antigen is found on vascular endothelial cells, some epithelial cells, activated, but not resting, T-cells, activated, but not resting, platelets, leukemic megakaryoblasts and a subset of bone marrow CD34+ cells. This antigen is not expressed on fresh peripheral blood lymphocytes (PBL). Poorly differentiated (CD34+, TdT+, CD7+) T-acute leukemias and rare cases of chronic myeloid leukemia in megakaryoblast crisis express the CD109 antigen. Furthermore, megakaryoblastoid cell lines (MO7e, MOLM-1) are CD109+. The CD109 antigen, strongly expressed on KG1a cell line with 20,000 binding sites per cell, may represent a very early marker for hematopoietic cells committed ...

Expression of major cytochrome P450 forms (P450) was followed in preparation of purified hematopoietic CD34+ stem and progenitor cells. Levels of transcripts as well as mature proteins were traced by quantitative real-time polymerase chain reaction and by Northern and Western blotting. P450 1B1 and …

Figure 1: Comparative Analysis of the Hematopoietic Progenitor Cells from Placenta, Cord Blood, and Fetal Liver, Based on Their Immunophenotype

Detailed drug Information for hematopoietic progenitor cells, cord blood Intravenous. Includes common brand names, drug descriptions, warnings, side effects and dosing information.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details ...

Research proven mouse monoclonal CD34 antibody. Excellent marker for hematopoietic progenitors and stem cells. CD34 protein is involved in differentiating HPCs into certain types of neurons. Also useful for studying endothelial cells, angigogensis and tumorigenesis. Designed for immunohistochemisitry and related applications. IHC image available.

Abrupt occlusion of coronary arteries causes MI, which leads to massive cardiomyocyte loss and consequently deterioration of cardiac function because cardiomyocytes have severely limited capacity to be divided and thus replace the damaged tissue. Progressive heart failure is a major cause of death or frequent hospitalization in patients after MI. Although MI is classified as vascular (coronary artery) disease, therapeutic strategies should be focused on regenerating not only blood vessels but also cardiac muscle to improve the poor prognosis of the disease.. Compelling evidence suggests that transplantation of bone marrow-derived CD34+ cells or cultured EPC-enriched population contributes to preservation of LV function after MI through enhancing ischemic neovascularization.10-12 The mechanism of this therapeutic effect was previously considered to be incorporation, differentiation, and proliferation of EPCs for new blood vessel formation.9,11,26 Recently, Badorff et al27 reported in vitro ...

The CD123 antigen, alias Interleukin-3 alpha receptor (IL-3Rα), belongs to the cytokine receptor family. It is constitutively expressed by committed hematopoietic stem / progenitor cells, by most of the myeloid lineage (CD13+, CD14+, CD33+, CD15low), and by some CD19+ cells, it is absent from CD3+ cells ...

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon. ...

Mobilized peripheral blood cells expressing the CD133 (AC133, Prominin-1) marker are generally known as primitive hematopoietic stem and progenitor cells (HSC and HPC).

Human Hematopoietic Stem Cell Expansion Cytokine Bundle contains the key components required for ex vivo Human Hematopoietic Stem Cell.

PRC2 Inhibition Counteracts the Culture-Associated Loss of Engraftment Potential of Human Cord Blood-Derived Hematopoietic Stem and Progenitor Cells

Assisted Reproductive Technologies and Haematopoietic stem cells Improvements for Quality and Safety throughout Europe ̶ an European Joint Action ...c

Laboratory equipment supplier for research and industry needs. Access now to the largest scientific products database in our online store.

Combined Growth Factors Enhance the Angiogenic Potential of Human Cord Blood-Derived Mononuclear Cells Transplanted to Ischemic Limbs

Gentaur molecular products has all kinds of products like :search , Alpha Dia \ Anti_Human CD45RA_PE_Cy5_conjugate \ CD45RAPC-100 for more molecular products just contact us